Since the 1980s, the development and increasingly widespread application of effective pharmacological lipid-lowering and antihypertensive agents, percutaneous intervention, and risk factor management strategies have contributed to efforts to lessen the burden of cardiovascular disease. Total age-adjusted cardiovascular mortality has fallen by >50% in most Western countries 1, 2 . This decline might be attributable in part to improved survival after myocardial infarction (MI); however, the ageing of the population counterbalances some of these advances in reducing coronary heart disease (CHD). As a result, the total economic burden of CHD might actually increase over time. In the USA, hospital case-fatality for acute MI between 1970 and 2010 has fallen from 16.0% to 1.9% and from 37.8% to 7.6% in patients aged <65 years and >65 years, respectively 3 . The number of hospitalizations for acute MI has also declined significantly in this same time period from 53 to 25 cases per 10,000 individuals 3 . The decline in mortality owing to MI and stroke results in part from a reduction in hospital fatality. The age-adjusted and sex-adjusted incidence of MI increased from 274 cases per 100,000 person-years in 1999, to 287 cases per 100,000 person-years in 2000; a decrease was observed each year thereafter, to 208 cases per 100,000 personyears in 2008, representing a 24% relative reduction 4 . The decline in the incidence of ST-segment elevation MI (STEMI) accounts for part of the overall reduction in acute MI. Analyses of data derived from the top 50 US cardiovascular hospitals demonstrated that the overall incidence of STEMI decreased by ~50% from 29 cases to 15 cases per 10,000 Medicare part A beneficiaries between 2002 and 2013 (REF. 5 ). By contrast, the proportion of patients in the USA with non-STEMI (NSTEMI) increased from 52.8% in 2002 to 68.6% in 2011 (REF. 6 ). The downward trend in STEMI can also be observed in many countries in the European Union and in the Middle East 7 . An Israeli study reported a significant decline in the incidence of STEMI from 4.70 cases per 1,000 persons in 2002 to 1.38 cases per 1,000 persons in 2012 (P <0.001), and a nonsignificant upward trend for the incidence of NSTEMI from 1.86 cases per 1,000 persons in 2002 to 2.37 cases per 1,000 persons in 2012 (REF. 8) . In this Review, we will discuss the clinical and pathological determinants that might underlie the observed secular trends in incidence and clinical Abstract | The concept of the 'vulnerable plaque' originated from pathological observations in patients who died from acute coronary syndrome. This recognition spawned a generation of research that led to greater understanding of how complicated atherosclerotic plaques form and precipitate thrombotic events. In current practice, an increasing number of patients who survive their first event present with non-ST-segment elevation myocardial infarction (NSTEMI) rather than myocardial infarction (MI) with ST-segment elevation (STEMI). The culprit lesions that provide the pathological substrate for NSTEMI can vary considerably from the so-called 'vulnerable plaque'. The shift in clinical presentation of MI and stroke corresponds temporally to a progressive change in the characteristics of human plaques away from the supposed characteristics of vulnerability. These alterations in the structure and function of human atherosclerotic lesions might mirror the modifications that are produced in experimental plaques by lipid lowering, inspired by the vulnerable plaque construct. The shift in the clinical presentations of the acute coronary syndromes mandates a critical reassessment of the underlying mechanisms, proposed risk scores, the results and interpretation of preclinical experiments, as well as recognition of the limitations of the use of population data and samples collected before the application of current preventive interventions.
presentation of MI. Furthermore, the implications of this shift in characterization of MI on the interpretation of preclinical experiments, and the use of pre-existent population data and proposed risk scores will also be discussed.
Risk factor modification
The reasons underlying the decline in cardiovascular morbidity and mortality might differ according to geographical region. The 2010 Global Burden of Disease study 9 described regional differences in the time trends in the incidence of ischaemic heart disease for 21 geographical regions. Lifestyle changes such as improved nutrition and reduced smoking, and the targeting of risk factors such as high blood pressure and high cholesterol levels have influenced mortality differentially between countries 10 . For example, an assessment of disease prevalence during the Cuban economic crisis of 1989-2000 linked reduced dietary caloric intake and increased physical activity with a reduction in cardiovascular mortality 11 . National regulatory agencies are actively changing policies to reduce the use of unnecessary food additives that influence health. The addition of transunsaturated fatty acids to food to improve taste and texture has been restricted, given its link with higher risk of CHD 12 . The Western diet is also high in salt, which originates primarily from processed foods. The FDA has issued proposed guidelines targeting the high sodium levels present in packaged food and restaurant meals 13 . The guidelines aim to reduce daily salt intake from the current recommended daily average of 3.4 g to 2.3 g (REF. 13 ). Reducing dietary salt by 3 g per day has been estimated to decrease the annual number of MI events by >50,000 (REF. 14).
Government-mandated smoking policies have restricted public smoking, and consequently yielded a major reduction in an individual's exposure to passive smoke [15] [16] [17] [18] . The smoking ban implemented in restaurants has been linked with a 5-20% decrease in hospital admissions for STEMI, predominantly in the non smoking population; the number of MI events among smokers has not changed 18 . The past few decades have also witnessed an increase in the use of pharmaceutical drugs to target risk factors such as hypercholesterolaemia and hypertension. The 2013 ACC/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults recommended statins for all individuals with a >7.5% risk of experiencing an MI or stroke in 10 years 19 . These evidence-based guidelines aimed to allocate statins to high-risk patients who harbour a greater burden of atherosclerosis and followed a process of shared decision-making between patients and clinicians 20 . Adherence to these recommendations might prevent as many as 450,000 atherosclerotic cardiovascular disease events over 10 years 21 . Given the strong link between high blood pressure and risk of stroke and coronary artery disease, the use of antihypertensive medications have also increased in the past decade. For each 5 mmHg reduction in systolic blood pressure, cardio vascular risk falls by 17%, regardless of the class of antihypertensive drug used 22, 23 . Furthermore, single and dual antiplatelet therapies are increasingly used for second ary prevention of cardiovascular events in patients with previous MI 24, 25 . Beneficial changes in diet and lifestyle, and advances in medical therapy have undoubtedly contributed to the reduction in STEMI incidence in the past few decades (FIG. 1) . However, in the same time period, increases in average BMI and incidence of diabetes melli tus in individ uals living in developed countries might have offset the decline in incidence of MI and stroke. Controversy persists regarding the BMI value that confers the lowest risk of cardiovascular disease and death. Although average BMI has increased over time in most countries, the overall prevalence of cardiovascular risk factors might also be decreasing among patients with obesity. Indeed the BMI associated with the lowest allcause mortality increased by 3.3 kg/m 2 from three Danish cohorts enrolled from 1976-1978 through to 2003 ). Nevertheless, the previously reported increase in the incidence of obesity seems to be slowing 27 . Age is a predominate risk factor for the development of CHD. Despite the encouraging reduction in ageadjusted cardiovascular morbidity and mortality during the past decade, the ageing population portends an absolute increase in this burden. Although a decline in cardiovascular and stroke mortality has been observed since 2011, total coronary and stroke mortality is still projected to increase by ~18% by 2030 in the USA 28 . However, the models used for this prediction have engendered debate; when secular trends towards risk factor reduction are incorporated into the calculations, coronary mortality is instead predicted to fall ~27% by 2030, and stroke mortality is not expected to change 29 .
Diagnosis and patient reclassification
Only a minority of individuals who present for urgent care for a chest complaint actually receive a diagnosis of MI. Early diagnosis is essential to differentiate between high-risk patients who require invasive treatment for preservation of cardiac function and low-risk patients who can be discharged. High-sensitivity assays for cardiac troponin can be used as a diagnostic tool within the first hour of presentation [30] [31] [32] [33] . The advent of even more sensitive assays for troponin will undoubtedly lead to increased reclassification of 'unstable angina' to NSTEMI, resulting in no change or an increase in the incidence of NSTEMI, whereas STEMI rates are expected to decrease 34, 35 . In this context, the fact that
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European and US guidelines differ in the strength of recommendation regarding the use of high-sensitivity assays for troponin in the diagnosis of NSTEMI merits consideration 36 .
Trends in clinical presentation
Improved risk factor control is undoubtedly associated with reduced incidence of MI and stroke, but whether it contributes to reported atherosclerotic lesion 'stabilization' and the subsequent shift in clinical presentation from STEMI to NSTEMI is unknown. Serial imaging and pathological studies revealed that statin treatment reduces lipid content and increases the relative collagen content of human plaques, features thought to be involved in the stabilization of lesions [37] [38] [39] [40] [41] . These alter ations in human plaque morphology correspond with the changes in lesion characteristics observed in experimental animals that are induced by lipid-lowering effects of diet or statin therapy 42 . Whether the cessation of smoking or the use of antihypertensive drugs can produce similar effects on atherosclerotic plaque characteristics is yet to be investigated.
The presenting clinical symptoms of coronary artery disease or cerebral ischaemia can reflect the under lying pathological mechanism that leads to the ischaemic event. Much of the thinking in this regard over the past decades has focused on the concept of the 'vulnerable plaque' . This concept was conceived through autopsy studies performed in the latter decades of the twentieth century, and has proven to be a highly useful guide to understanding the pathophysiology of acute coronary syndrome (ACS) [43] [44] [45] . Current data, however, suggest that the observed shift in the acute clinical manifestations of CHD reflects a concomitant change in the underlying pathological substrates 46 . These considerations prompt a re-evaluation of the relative importance of the so-called 'vulnerable plaque' in the current era.
The concept of the vulnerable plaque Atherosclerosis causes clinical disease by narrowing the lumen or by precipitating thrombi or atheroemboli that impede blood flow to the heart, brain, or lower extremities. Histopathological studies of coronary arteries in patients who died of acute MI revealed that large atheroma size, a thin fibrous cap, and the presence of abundant inflammatory cells (mainly macrophages) contributed to fatal thrombotic events [43] [44] [45] . However, the pathophysiological role of calcium in plaque destabil ization might be a double-edged sword. Calcified noduli can protrude in the lumen, and lead to subsequent thrombus formation 47 . Conversely, calcification is associ ated with 'plaque healing' , given that calcium density is inversely related to CHD risk, and statin use promotes atheroma calcification 48, 49 . The pioneering postmortem studies on vulnerable plaques proposed that plaque rupture, resulting in thrombosis, is responsible for two-thirds to three-quarters of all fatal acute MI events [43] [44] [45] . This 'vulnerable plaque' concept has inspired the work of legions of vascular biology researchers, and has been used as a target for imaging and drug discovery, and as a model of atherosclerosis in preclinical experiments.
Despite the value of the vulnerable plaque construct in orienting our understanding of the mechanisms of ACS, this concept has encountered challenges, and might not be as applicable for disease classification in current era. A re-evaluation of this concept is timely, given the shift in clinical presentations of patients with ACS from STEMI to NSTEMI. This shift in clinical presentation is relevant for both ACS and stable coronary artery disease. However, autopsy studies on plaques that cause stable coronary syndromes are lacking, and insights into the pathogenesis of stable coronary syndromes are derived mostly from in vivo imaging studies. Compared with patients presenting with acute MI, those with stable angina tend to have less coronary arterial plaque burden, less expansive remodel ling, less evidence of inflammation and neovascularization, and fewer thrombi 50, 51 . Furthermore, although autopsy analy sis of culprit lesions respons ible for ACS have revealed plaque rupture, a proportion of occlusive thrombi complicate lesions that lack the typical thin-capped characteristics of ruptured lesions, a morphological appearance known as 'superficial erosion' (REFS 52, 53) . These nonruptured thrombotic lesions are more frequently observed in women, and can Nature Reviews | Cardiology Depicted are atherosclerotic vessels with a lipid-rich 'vulnerable' lesion (dark grey area in the lesion represents lipid-rich necrotic core), which are more prevalent in lesions associated with STEMI (left side of figure) . At present, with the decline in STEMI incidence, this lesion type is less frequently associated with the thrombotic event. Vessels with a classically defined stable lesion are more frequently observed in the presence of stable angina and non-STEMI (NSTEMI). The proportion of this stable lesion type has increased over time (right side of figure) ACS, acute coronary syndrome.
cause up to 50% of acute coronary deaths 52 . In men, up to 25% of acute coronary deaths can originate from non ruptured, eroded lesions. Pathological and in vivo imaging studies suggest that the change in clinical presentation of ACS towards NSTEMI correlates temporally with a lower prevalence of thrombosis provoked by ruptured plaques (TABLE 1) . Patients with NSTEMI have a much lower prevalence of ruptured plaques (43%) than those with STEMI (71%) (FIG. 2) . The evolution in the characteristics of atherosclerotic disease might reflect not only secular trends in risk factors and therapeutic interventions, but also demographic shifts in the patients enrolled in studies.
Another major challenge to the 'vulnerable plaque' concept arose from the findings that lesions with the histological characteristics associated with 'vulnerability' commonly occur in atherosclerotic arteries in the absence of clinical disease manifestation. Approximately 75% of femoral and coronary atheromata in individuals without acute manifestations show signs of inflammation in the cap and shoulder regions 54 . Leukocyte activation markers are increased in the venous effluent from regions not supplied by the culprit lesions in patients with ACS 55 . The PROSPECT study 56 reported that <5% of coronary artery plaques characterized as thin-capped fibroatheromata on intravascular imaging caused an acute event during a 3-year follow-up period. Thus, the vast majority of so-called 'vulnerable plaques' are in fact quite stable. Moreover, these data support the dispersed and variable nature of such lesions, challenging the validity of approaches that aim to identify and treat an isolated vulnerable plaque 57 .
Crosstalk between plaque and circulation
In PROSPECT 58 , circulating C-reactive protein (CRP) concentrations strongly predicted the rate of major adverse coronary events: 13.8% of thin-cap fibroatheromatous nonculprit lesions were linked to a major adverse event during follow-up in patients with high levels of CRP (>10 mg/l), compared with only 1.9% in those with lower levels of CRP (<3 mg/l). The number of high-risk thin-cap fibroatheromatous non culprit plaques did not differ between the high-CRP and low-CRP groups. These results strengthen the view that in the absence of augmented inflammation (as indicated by levels of CRP), few of these lesions go on to provoke an event 58 . Indeed, the thin-capped morphology ascribed to vulnerable plaques has a limited positive predictive value for the occurrence of an acute event. For example, in the PROSPECT study cohort 59 , 105 plaque ruptures present in 100 coronary arteries complicated lesions that lacked the so-called 'vulner able morphology' , as interrogated by virtual histology or intravascular ultrasound. During the 3-year follow-up period, the incidence of major adverse cardiac events did not differ between the patients with and those without subclinical, nonculprit plaque ruptures 59 . Thus, the consequences of plaque disruption depend not only on the 'solid state' of atheroma itself, but also on the presence of other aetiological determinants, such as the coagulation status of the blood 60 . Coronary CT follow-up studies reported an almost identical number of ACS events associated with the presence of high-risk plaques (characterized by positive remodelling and low attenuation) and those considered to be low-risk plaques 61 . In addition, both the morphological character istics and dynamics of a lesion can critically influence its propensity to provoke MI 62, 63 . Rapid progression of lesion size could result from intraplaque bleeding, a feature of a plaque that is predictive of future adverse events, but not included in the current definitions of the vulnerable plaque 64, 65 .
Time-dependent changes in the plaque
The concept of the vulnerable plaque should be adjusted as the characteristics of the human plaque evolve over time, to synchronize with the shifts in the clinical presentation and risk profile of patients with ACS. The change in thrombotic complications of coro nary artery plaques over time is also accompan ied by a significant decline in the incidence of fatal stroke [66] [67] [68] . The tandem changes in coronary and cerebral events suggest a systemic rather than a local change in athero sclerotic disease progression. Investigators of Athero-Express 69 , an ongoing Dutch biobank study designed to determine plaque characteristics that are associated with cardiovascular events have collected atherosclerotic carotid plaques since 2002. Analysis of these plaque (FIG. 3) . The time-dependent shift from plaques with histo logical features associated with 'instability' towards those with characteristics generally ascribed to ' stable' plaques occurred in lesions retrieved from both symptomatic and asymptomatic patients. Therefore, it seems that there is not only a time-dependent decline in major cardio vascular event rates, but even within the remaining diseased but event-free or asymptomatic patient group, the character istics of plaques have shifted towards features associated with stability.
Shift in pathogenetic basis of ACS
Several observations support the proposition that the cardiovascular clinical and research communities face a transition that challenges the current view of the prevailing mechanisms underlying acute major clinical events owing to atherosclerotic disease. These include the decline in death rate and hospitalizations owing to ACS and stroke; the relative increase in NSTEMI versus STEMI in patients presenting with an ACS; and finally, the changes in plaque characteristics of culprit lesions that underlie acute thrombotic complications that cause stroke and ACS (FIG. 3) . This transition in our understanding of the mechanisms involved in symptomatic ACS coincides with temporal changes in total atherosclerotic disease burden in the general population. In diagnostic procedures, the rate of abnormal studies involving the use of single-photon emission CT declined from 40.9% in 1991 to 8.7% in 2009 (REF. 70) . This transition appears to be ongoing, and the search for mechanistic explanations has important implications for clinical practice, for public health, and for future research directions.
Plaque erosion
Several morphological, cellular, and molecular features of the nonruptured atherosclerotic lesion work together to provoke thrombotic events. As noted above, thrombotic events can be caused by fibrous athero mata that lack a thin fibrous cap by a mechanism distinct from rupture, known as plaque erosion. The term 'erosion' suggests that a dysfunctional or absent layer of endothelium promotes thrombosis, but the mechanisms of such an erosive event have received scant attention. One possible mechanism of plaque erosion is endothelial apoptosis, which has been shown to induce arterial thrombosis in rabbits 71 . Inflammatory cell recruitment might accelerate this process, although most, but not all, studies find few inflammatory cells within lesions complicated by thrombosis attributed to superficial erosion 44, 72 . An in vitro experi ment demonstrated that mast cell release of chymase together with tumour necrosis factor-α (TNFα) can induce endothelial apoptosis 73 . Furthermore, an observational study in human coronary segments showed co-localization of subendothelial mast cells and intraluminal platelet microthrombi, suggesting that desquamation of the endothelium by mast cell proteases can activate the endothelium 74 . Endothelial cells can generate endogen ous reactive oxygen species (ROS) that subsequently promote cell death. Various proinflammatory and proatherosclerotic factors such as angiotensin II and TNFα can induce ROS generation in endothelial cells 75 . The neutrophil cell lineage might also participate in plaque thrombosis without rupture, although likely after initiation of the process 76 . Neutrophils contain a high quantity of myeloperoxidase, a pro-oxidant enzyme that circulates at higher concentrations in patients with ACS owing to an eroded culprit lesion compared with patients with a ruptured culprit plaque, as defined by optical coherence tomography. In addition, luminal thrombi on eroded coronary artery plaques at post mortem examination contain more myeloperoxidase-positive cells than thrombi caused by ruptured plaques, suggesting the presence of neutrophils 77 . Neutrophils can release strands of DNA, called neutrophil extracellular traps (NET), which can promote primary and secondary haemostasis by inducing platelet aggregation and activating coagulation. In addition, NETs can inhibit fibrinolysis and thereby enhance clot stability. Neutrophil recruitment to the vessel wall, and subsequent NET generation can contribute to a highly procoagulant environment that could amplify, propagate, and sustain arterial thrombi 78 .
Clinical and research implications
The evolving characteristics of atherosclerotic plaques that lead to clinical disease have implications for both clinical practice and research. A multitude of experimental studies that often use genetically modified mice with exaggerated cholesterol levels employ various genetic or pharmacological techniques to generate a stable or unstable plaque phenotype. The current human pathological and clinical findings reviewed here cast serious doubt on the applicability of such studies to contemporary clinical practice. Indeed, the ongoing shift in the incidence in atherosclerotic disease manifestation and the responsible pathological substrates have implications on the interpretation of results from previous basic, translational, and clinical studies. Extrapolation of observations from the past century, obtained in a bygone era of therapy and risk factor exposure, warrants a re-evaluation of the major current questions for research, and the interpretation of experimental results.
Outdated population and cohort-based biobanks.
The decline in the age-adjusted incidence of events owing to atherosclerosis, the altered risk profiles, and the increased use of effective preventive medications call into question the relevance of current plaque or blood specimens frozen for future research purposes. The translational value of observations made on such resources for current practice raises even further concerns if both the sampling of specimens and the monitor ing of cardiovascular events took place >1 decade ago. Circulating biomarkers that can aid in predicting atherosclerotic disease progression and inform the effects of novel therapies are still needed [79] [80] [81] . The concept that acute atherosclerotic events commonly complicate highly inflammatory and proteolytic plaques has driven many biomarker discovery programmes. Numerous proposed biomarkers with predictive value for MI, such as myeloperoxidase 82 , CRP measured by high-sensitivity assay, and soluble intercellular adhesion molecule 1 (REF. 83 ), arise from the idea that vascular inflammation participates in the pathogenesis of cardiovascular events. Although this concept is supported by numerous studies, it might be less applicable to the growing group of patients with ischaemic heart disease receiving current standard-of-care treatment. These considerations indicate that the time window of enrolment and blood sampling can profoundly influence the observational associations between biomarkers, the burden of atherosclerotic disease, and clinical events.
Imaging of the at-risk plaque. Numerous imaging modalities have been developed to assess the characteristics of the rupture-prone plaque in vivo. Ultrasoundbased virtual histology 84 , Raman spectroscopy 85 , thermography 86 , near-infrared spectroscopy 87 , optical coherence tomography 88, 89 , and a variety of molecular imaging strategies have been developed to measure inflammatory thin-cap fibroatheroma. Noninvasive MRI can be used to identify intraplaque haemorrhage, a plaque characteristic that might predict future adverse cardiovascular events and progression of luminal narrow ing 90, 65 . Imaging of features that are associated with the classically defined thin-cap fibroatheroma might help to assess the efficacy of plaque-stabilizing drugs. However, clinicians and researchers need to take into account secular trends in atheroma with advances in therapy. For example, atorvastatin reduced carotid intima-media thickness in the 2001 ASAP study 91 compared with pravastatin, but the addition of ezetimibe did not reduce carotid intima-media thickness in the 2008 ENHANCE trial 92 . In this context, the use of carotid intima-media thickness as a measure of drug efficacy might be challenged, but this result might have arisen because the use of standard-of-care treatment in the interim lowered the baseline intima-media thickness to the 'normal' range, obscuring the possible effect of additional therapy 91, 92 . The lower incidence of STEMI and the concomitant increase in less lipid-laden and inflamed plaques in the era of statin therapy raise similar notes of caution regarding the interpretation and goals of imaging studies. Referred to as 'the myth of the vulnerable plaque' , researchers have proposed that the management of patients at risk of MI mandates a greater focus on atherosclerotic disease burden than on features of individual plaques 57 , an inference that is supported by studies assessing the use of coronary CT angiography in patients with nonobstructive coronary artery disease 93 . The health-care system has generally targeted the most aggressive risk factor management strategies to the highest-risk individuals. Risk scores such as the Framingham score have served as a comparator to explore the added value of novel biomarkers on top of traditional risk factors for the prediction of CHD 94 . The arguments presented here, notably regarding the trend towards less STEMI and altered characteristics of culprit plaques, might affect the current clinical relevance of the most widely used cardiovascular risk scores. Most population-based cohorts that have provided event rates for risk assessment have undergone follow-up of ≥10-12 years, and included individuals who had blood sampled before 1990, or as far back as the 1960s. At inclusion, these individuals were almost certainly exposed to different risk factors (such as increased passive smoking), received different medical treatments, and had a different lifestyle compared with contemporary cohorts. Moreover, clinical end points in previous eras included more STEMI, higher case fatality rates for ACS, and as mentioned previously, a different underlying pathological substrate for disease. The application of cohorts sampled in prior eras for use in current risk score assessment has contributed to the recent debate on the use of statins based on the new AHA/ACC/ASCVD risk scores 95 . The newly developed risk scores proposed by the ACC/AHA might overestimate cardiovascular events by 37-154% in men and 8-67% in women, when discrimination and calibration was compared with other risk scores and the actual observed events 96 . Cardiovascular risk scores should undergo external validation in current populations before clinical use. For example, the use of external valid ation cohorts that have been sampled more recently than those used in calculating the risk prediction algorithm would incorporate secular improvements in overall health and lifestyle patterns 95 . Indeed, the cohorts used for the newly developed ACC/AHA risk prediction models originated from cohorts assembled before 1990 (REF. 97 ). Risk prediction algor ithms should not only discriminate between individ uals with or without disease, but must also be calibrated so that predicted risk estimates match as closely as possible to the observed risk in external popu lations 98 . A study published in 2016 reported that the ACC/AHA Pooled Risk Equation substantially overestimated the 5-year risk of atherosclerotic cardio vascular events 99 . Indeed, risk score calibration is among the most important issues in preventive cardiology 100 . Risk scores should be validated using cohorts that reflect current practice as closely as possible. This goal presents a challenge, because accumulation of events requires a long follow-up period, and external validation utilizes cohorts enrolled >1 decade ago.
Implications for the interpretation of animal experiments. The slow progression of human atherosclerosis hampers the assessment of the natural history of this disease, which would ideally involve extensive serial examinations. Laboratory studies generally use in vitro cell-based approaches or animal models to provide insight into mechanisms of pathogenesis and the effects of different therapies. The generation of genetically modified mice on an atherosclerotic background exponentially increased the number of publications on genes that might influence plaque growth and lesion characteristics 101, 102 . The data obtained from murine animal experiments are interpreted in the context of the early pathological descriptions of the vulnerable plaque, which were though to be responsible for triggering most thrombotic occlusive events in humans 103 . Despite its undeniable utility for probing specific molecular mechanisms, atherosclerosis-prone mice differ from humans with arterial disease in many respects 104, 105 . These differences should be considered when assessing the clinical translatability of the data derived from atherosclerotic mice. Furthermore, patients with atherosclerotic lesions now usually receive numerous medical interventions and often experience comorbidities that cannot be mimicked in mouse models. Few established experimental approaches described in animals mimic aspects of spontaneous luminal thrombus formation on stable atherosclerotic plaques 106 .
Conclusions
In medicine, as in many other pursuits, we should strive to keep eyes on a moving target. The edifice of the 'vulnerable plaque' arose from strong clinical research studies, and a greater understanding of the pathophysio logy underlying the lipid-rich atheromatous plaque has resulted in therapeutic advances. The benefits that have emerged from these advances for public health merit considerable celebration. In the past decades, extra ordinary inroads have been made against athero sclerotic disease, akin to the transformative effect of the introduction of antibiotics on infective diseases. However, the very measures that have enabled our extraordinary success in improving clinical outcomes in those at risk have altered the disease itself. Moreover, the improved understanding and treatment of classic risk factors for atherosclerosis has occurred in the face of a countervailing worldwide increase in obesity and metabolic derangements that might drive the next wave of epidemic cardiovascular disease. To confront the residual burden of disease in an era of highly effective LDL-lowering therapies, the widespread availability of strategies for management of hypertension, and societal measures to combat tobacco abuse, we must prepare to wage battle against the disease of today and tomorrow, not that of yesteryear. To meet this challenging objective, we will need to reconsider the implications of data collected before the new millennium for current practice, and all the changes in therapy and the risk factor environment that have ensued. Biomarker and drug target discovery programmes should be cautious when interpreting data derived from samples that were obtained >10-15 years ago, risk scores should be calibrated by using studying cohorts that resemble the current population, and developers of novel imaging modalities should look beyond the characteristics of the isolated vulnerable lesion, and embrace the importance of total plaque burden.
